Polaris Partners

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

Tome Biosciences is a biotechnology company specializing in programmable gene insertion technology. Utilizing CRISPR, the company develops methods to insert genetic sequences of any size at various locations within any genome. This innovative approach aims to enhance the ability to detect and eliminate deoxyribonucleic acid from similar bacteriophages during infections. By advancing cell and genome engineering, Tome Biosciences seeks to provide effective therapeutic solutions for patients, paving the way for significant advancements in genetic medicine.

Triveni Bio is a biotechnology company specializing in the development of novel antibody therapies for immunological and inflammatory disorders. The company employs a genetics-driven precision medicine approach to identify patients most likely to respond to its treatments, aiming to accelerate drug development and improve the effectiveness and safety of therapies.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

EpiBiologics is a biotechnology company focused on developing antibody-based targeted therapies aimed at membrane and extracellular proteins that contribute to various diseases. Utilizing its proprietary EpiTAC platform, EpiBiologics creates therapeutics designed to degrade these disease-driving proteins, addressing the underlying biology of a wide range of disorders. The company's innovative approach enables researchers to manipulate cellular proteostasis, offering potential advancements in the treatment of challenging health conditions.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Paratus Sciences is a biotechnology company focused on enhancing human health and health security through the study of bat biology. By investigating the unique characteristics of the bat genome, the company aims to identify and develop therapeutics for various diseases. Leveraging insights gained from bat biology, Paratus Sciences seeks to enable patients to combat and potentially cure the diseases they face. Through its innovative approach, the company aspires to contribute significantly to advancements in medical treatments and public health.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing adeno-associated virus (AAV) vectors for gene therapy applications. Its innovative platform utilizes artificial intelligence, next-generation DNA synthesis, and high-throughput sequencing to design and optimize AAV capsids, which are crucial for delivering therapeutic genes effectively and safely. By leveraging machine learning and quantitative experimentation, Dyno Therapeutics aims to revolutionize the design of gene vectors, focusing on enhancing cell-targeting capabilities. The company's approach seeks to advance the field of gene therapy, making it possible for researchers to access novel AAV vectors that can facilitate more efficient in vivo delivery of new treatments.

Egenesis Inc. is a biotechnology company focused on gene editing and genome engineering to create human transplantable organs, tissues, and cells. Established in 2015 and headquartered in Cambridge, Massachusetts, with an additional office in New York City, Egenesis aims to address the global organ shortage by developing solid organs and therapeutic cell transplantation solutions for various diseases. The company utilizes a gene editing platform that incorporates techniques such as single-cell cloning and somatic cell nuclear transfer, which are essential for creating human-compatible organ tissues and cells. Egenesis is particularly engaged in advancing programs related to kidney and islet cell transplantation, striving to provide alternative treatment options for patients with life-threatening conditions.

Noema Pharma AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company focuses on developing innovative therapeutic products for orphan neurological disorders characterized by imbalanced neuronal networks. Its research and development efforts are dedicated to addressing disabling symptoms associated with conditions affecting the nervous system, such as Tuberous Sclerosis Complex, Trigeminal Neuralgia, and Tourette syndrome. By creating novel therapies, Noema Pharma aims to enhance the quality of life and improve patient outcomes for those suffering from these challenging disorders.

Neogene Therapeutics, Inc., founded in 2018 and based in New York, develops innovative T cell therapies aimed at treating cancer. The company specializes in creating personalized engineered T cells that target mutated proteins, known as neo-antigens, found in cancer cells as a result of DNA mutations. By leveraging advanced technologies, Neogene isolates neo-antigen specific T cell receptor genes from tumor biopsies, which are routinely collected during cancer treatment. These tumor-infiltrating lymphocytes often express T cell receptors that can recognize and attack cancer cells displaying neo-antigens. Utilizing state-of-the-art DNA sequencing, synthesis, and genetic screening, Neogene's proprietary platform enables the identification of these specific T cell receptors with high sensitivity and at scale, ultimately enhancing the efficacy of cancer treatments.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Vico Therapeutics B.V. is a biotechnology company based in Leiden, the Netherlands, founded in 2019. The company specializes in the development of RNA modulating therapies aimed at treating rare neurological disorders. Vico Therapeutics focuses on conditions such as spinocerebellar ataxias, Huntington’s disease, and Rett syndrome, which encompass a range of hereditary and neurodevelopmental disorders. By discovering and developing innovative therapies, the company aims to address significant unmet medical needs in the central nervous system, providing new treatment options for patients and healthcare professionals.

QurAlis Corporation is a clinical-stage biotechnology company focused on discovering and developing therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. Established in 2016 and based in Cambridge, Massachusetts, QurAlis employs proprietary platforms and biomarkers to create precision medicines that target genetically validated disease-causing alterations. The company’s pipeline includes innovative treatments aimed at specific subtypes of ALS, such as therapies that restore dysfunctional cellular waste clearance, manage overactive neurons, and eliminate toxic proteins. Through its advanced antisense oligonucleotides and small molecule programs, QurAlis seeks to halt disease progression and significantly improve patient outcomes for those affected by ALS.

Dyno Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, founded in 2018. The company specializes in developing adeno-associated virus (AAV) vectors for gene therapy applications. Its innovative platform utilizes artificial intelligence, next-generation DNA synthesis, and high-throughput sequencing to design and optimize AAV capsids, which are crucial for delivering therapeutic genes effectively and safely. By leveraging machine learning and quantitative experimentation, Dyno Therapeutics aims to revolutionize the design of gene vectors, focusing on enhancing cell-targeting capabilities. The company's approach seeks to advance the field of gene therapy, making it possible for researchers to access novel AAV vectors that can facilitate more efficient in vivo delivery of new treatments.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company based in San Mateo, California, focused on the discovery and development of innovative cancer therapeutics. Established in 2017, the company aims to address historically challenging cancer targets through precision medicine. Its primary product candidates include entospletinib, a selective inhibitor of spleen tyrosine kinase intended for acute myeloid leukemia patients, and KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9 for treating MYC-amplified solid tumors. Kronos Bio employs advanced technologies, such as high-throughput small-molecule microarrays and targeted protein degradation, to identify potent and selective compounds that target dysregulated transcription factors and other key drivers of oncogenic signaling.

Genetic Foresight’s mission is to prevent adverse drug reactions, increase therapeutic success rates, and minimize healthcare costs by enabling clinicians to make informed decisions. Founded in 2016, Genetic Foresight provides a genetic test that sequences targeted segments of patients' genomes as well as a comprehensive prescription decision platform that incorporates drug-genome, drug-drug, drug-disease, personal health, lifestyle, and medical and family histories to predict drug response. This allows the clinician to more safely and effectively prescribe medication based on the patient. The report is updated based on newly generated research, newly created drugs, and newly prescribed drugs, making it a lifetime test.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

CAMP4 Therapeutics Corporation is a bioinformatics company founded in 2015 and based in Cambridge, Massachusetts. The company specializes in gene regulation circuitry, focusing on the fundamental causes of diseases by manipulating gene expression. Utilizing its proprietary 4-D gene circuitry platform, CAMP4 codifies the activation of approximately 24,000 human genes into a discrete set of combinatorial rules based on existing cellular signaling pathways. This innovative approach allows CAMP4 to effectively control gene production, thereby accelerating the development of new therapies. By employing this technology, the company aims to streamline the drug development process, significantly reducing both the time and risks associated with bringing new medicines to patients.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

KSQ Therapeutics, Inc., founded in 2015 and based in Cambridge, Massachusetts, specializes in precision functional genomics to discover innovative drug therapies. The company employs a novel approach to research and development that emphasizes de-risking prior to the creation of therapeutic candidates. Utilizing its proprietary CRISPRomics™ drug discovery engine, KSQ Therapeutics has mapped the functions of human genes across various diseases, enhancing its understanding of disease biology. This comprehensive insight enables the identification and validation of high-confidence, patient-specific drug targets. As a result, the company is focused on developing medicines that have significant potential to improve patient outcomes and has established a pipeline of preclinical discovery programs.

Genomics Medicine Ireland is an Irish life sciences company conducting a substantial research study across Ireland. Its primary focus is to investigate the human genome, aiming to understand the relationship between genetics, health, and disease.

Kallyope Inc. is a biotechnology company based in New York City that focuses on understanding the gut-brain axis to develop innovative therapeutics and consumer products aimed at enhancing human health. Established in 2014, Kallyope employs advanced technologies, including sequencing, computational biology, neural imaging, and human genetics, to explore gut-brain biology. The company aims to address significant unmet medical needs, such as diabetes, obesity, gut disorders, inflammatory diseases, migraines, and allergies, by creating effective and user-friendly oral agents. Kallyope's team consists of experienced scientists from leading institutions, working alongside a skilled team with a strong track record in drug discovery and development. Through its research, Kallyope seeks to deliver transformative solutions that improve overall health outcomes.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Arivale Inc. is a wellness services provider that focuses on helping individuals optimize their health and prevent diseases through a scientific approach. Founded in 2014 and headquartered in Seattle, Washington, the company analyzes various aspects of an individual's health, including genetics, blood markers, microbiome data, and lifestyle choices. By combining this personalized data with tailored coaching and support from a clinical team, Arivale delivers actionable recommendations to enhance wellness. Their program not only empowers individuals to make informed decisions regarding diet and exercise but also contributes to a longitudinal dataset that aids in the discovery of innovative health improvement methods. Overall, Arivale is dedicated to providing a comprehensive and intimate view of well-being to enhance the quality of life for its members.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

WuXi NextCODE operates as a clinical diagnostics company specializing in sequence-based genomics. The firm provides a platform that assists physicians in obtaining critical clinical insights, enabling rapid and accurate diagnoses for patients. Its services include genome interpretation, data analysis, and data mining, along with security and data protection measures. The company also offers custom integration services and both clinical-grade and non-clinical-grade sequencing. With technology developed over 16 years at deCODE genetics, WuXi NextCODE aims to facilitate the integration of genomic data into patient care and diagnosis. Based in Cambridge, Massachusetts, the company was acquired by WuXi AppTec in 2015 and has since focused on addressing the challenges of genome interpretation and big data in healthcare.

WuXi NextCODE operates as a clinical diagnostics company specializing in sequence-based genomics. The firm provides a platform that assists physicians in obtaining critical clinical insights, enabling rapid and accurate diagnoses for patients. Its services include genome interpretation, data analysis, and data mining, along with security and data protection measures. The company also offers custom integration services and both clinical-grade and non-clinical-grade sequencing. With technology developed over 16 years at deCODE genetics, WuXi NextCODE aims to facilitate the integration of genomic data into patient care and diagnosis. Based in Cambridge, Massachusetts, the company was acquired by WuXi AppTec in 2015 and has since focused on addressing the challenges of genome interpretation and big data in healthcare.

AgBiome, LLC is a biotechnology company based in Durham, North Carolina, that focuses on the agriculture industry through the development of biological products. Founded in 2012, AgBiome leverages its expertise in plant-associated microbes and modern genomics to create innovative solutions aimed at enhancing plant health, pest resistance, and crop yields. The company addresses critical agricultural challenges, including soil-borne diseases, insects, and nematodes, by offering fungicides and a platform that identifies and screens diverse microbial strains. AgBiome collaborates with prominent agricultural partners to accelerate discovery processes and broaden the reach of its sustainable products in global markets. With a dedicated team of over 85 employees and a state-of-the-art laboratory and greenhouse facility, AgBiome is committed to improving food production responsibly.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

DeCODE Genetics is a biopharmaceutical company based in Reykjavik, Iceland, founded in 1996. It focuses on analyzing the human genome to identify genetic variants associated with common diseases. The company utilizes population studies to uncover key genetic risk factors for various conditions, including cardiovascular disease and cancer. DeCODE Genetics develops diagnostic tests and technologies aimed at improving the treatment, diagnosis, and prevention of these diseases. By leveraging its expertise in chemistry and structural biology, the company also supports clients in the healthcare sector with DNA-based reference laboratory tests and consumer genome analysis services, which help assess individual risk for common diseases.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Genocea Biosciences, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patient-specific CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. This technology enables Genocea to develop personalized immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, as well as GEN-011, a neoantigen adoptive T cell therapy, and GEN-010, a neoantigen vaccine program. Additionally, the company has pursued immunotherapies for other diseases, such as GEN-003, aimed at treating genital herpes, and it maintains a pre-clinical program focused on personalized cancer vaccines. Founded in 2006, Genocea is dedicated to addressing significant unmet medical needs through its advanced therapeutic approaches.

Athenix is a prominent company in the field of agricultural and industrial biotechnology, specializing in the development of innovative products, technologies, and processes for agricultural and chemical applications. The company has established a robust infrastructure dedicated to the discovery of new genes, which are then developed into practical solutions that address the needs of its customers. Athenix focuses on creating plants, microbes, and enzymes that provide resistance to insects and nematodes, as well as herbicide tolerance. Additionally, the company is involved in the discovery of genes and proteins that are applicable in the chemical and animal feed industries.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Athenix is a prominent company in the field of agricultural and industrial biotechnology, specializing in the development of innovative products, technologies, and processes for agricultural and chemical applications. The company has established a robust infrastructure dedicated to the discovery of new genes, which are then developed into practical solutions that address the needs of its customers. Athenix focuses on creating plants, microbes, and enzymes that provide resistance to insects and nematodes, as well as herbicide tolerance. Additionally, the company is involved in the discovery of genes and proteins that are applicable in the chemical and animal feed industries.

Athenix is a prominent company in the field of agricultural and industrial biotechnology, specializing in the development of innovative products, technologies, and processes for agricultural and chemical applications. The company has established a robust infrastructure dedicated to the discovery of new genes, which are then developed into practical solutions that address the needs of its customers. Athenix focuses on creating plants, microbes, and enzymes that provide resistance to insects and nematodes, as well as herbicide tolerance. Additionally, the company is involved in the discovery of genes and proteins that are applicable in the chemical and animal feed industries.

Adnexus, a Bristol-Myers Squibb R&D Company, specializes in the discovery and development of Adnectins, a unique class of targeted biologics. These proteins are engineered to block or stimulate therapeutic targets to combat various diseases, addressing significant medical needs in oncology, immunology, and cardiovascular health. Utilizing a proprietary protein engineering system known as PROfusion™, Adnexus can generate a vast library of over 10 trillion potential Adnectins. This technology enhances the efficiency of identifying candidates with desirable therapeutic properties. Among its product candidates is Angiocept/CT-322, an anti-angiogenesis agent aimed at treating cancer by inhibiting the VEGFR-2 pathway. Since its acquisition by Bristol-Myers Squibb in 2007, Adnexus has further advanced its capabilities in developing innovative medicines to improve patient outcomes.

Athenix is a prominent company in the field of agricultural and industrial biotechnology, specializing in the development of innovative products, technologies, and processes for agricultural and chemical applications. The company has established a robust infrastructure dedicated to the discovery of new genes, which are then developed into practical solutions that address the needs of its customers. Athenix focuses on creating plants, microbes, and enzymes that provide resistance to insects and nematodes, as well as herbicide tolerance. Additionally, the company is involved in the discovery of genes and proteins that are applicable in the chemical and animal feed industries.